Fairness opinions › Bankers

Guggenheim Securities: healthcare fairness opinions

12 opinions in healthcare transactions, 2016-2024 — 12 to the target board. Each links to the filing and the full summary of analyses.

Opinions
12
2016-2024
Typical DCF discount rate
8.3%–10.0%
median of low / high · n=11
Terminal method
perpetuity growth 11
Median disclosed fee
$17.5M
n=10

Deals

AnnouncedTargetAcquirerSegment EVEV/EBITDAEV/RevDCF rate
2024-12-11 Patterson Companies Patient Square Capital Distribution and Equipment Services $4.1B12.0x0.61x8.6%–10.2%
2023-06-26 Amedisys UnitedHealth Group Home-Based Services $3.6B15.2x1.59x8.3%–10.5%
2021-01-04 Magellan Health Centene Managed Care $2.0B15.6x0.45x7.0%–8.0%
2019-11-04 Wright Medical Group StrykerCorp. Medical Devices and Supplies $4.1B14.6x3.49x7.0%–8.4%
2018-06-11 Envision Healthcare Holdings KKR Physician Groups $9.9B10.0x1.16x8.0%–9.0%
2017-12-19 Kindred Healthcare Humana/TPG/WCAS Hospitals $4.1B8.0x0.68x8.5%–9.5%
2017-11-16 Almost Family LHC Group Home-Based Services $933M14.3x1.16x8.5%–10.0%
2017-11-16 LHC Group Almost Family Home-Based Services $1.3B15.5x1.25x8.5%–10.0%
2017-02-13 ZELTIQ Aesthetics Allergan Medical Devices and Supplies $2.4B32.9x5.03x10.1%–11.8%
2016-12-02 Vascular Solutions Teleflex Medical Devices and Supplies $976M25.7x5.86x9.4%–11.4%
2016-09-27 EndoChoice Holdings Boston Scientific Medical Devices and Supplies $458M4.28x11.8%–13.8%
2016-04-28 St. Jude Medical Abbott Laboratories Medical Devices and Supplies $29B15.2x4.70x7.0%–8.5%

Segments: Medical Devices and Supplies (5) · Home-Based Services (3) · Distribution and Equipment Services (1) · Managed Care (1) · Physician Groups (1) · Hospitals (1)

Discount rates Guggenheim Securities has used

DealDiscount rateTerminalGrowth / exitImplied per share
Amedisys 2023 8.3%–10.5% perpetuity growth 2.0%–3.0% $63.75–$103.25
Magellan Health 2021 7.5%–8.5% perpetuity growth 1.0%–2.0% $87.75–$111.50
Wright Medical Group 2019 7.0%–8.4% perpetuity growth 2.0%–3.0% $22.25–$40.25
Envision Healthcare Holdings 2018 8.0%–9.0% perpetuity growth 1.0%–1.5% $34.75–$71.25
Kindred Healthcare 2017 8.0%–9.3% perpetuity growth 1.8%–2.3% $1.40–$10.34
Almost Family 2017 8.5%–10.0% perpetuity growth 1.8%–2.3% $41.71–$56.52
LHC Group 2017 8.5%–10.0% perpetuity growth 1.8%–2.3% $41.71–$56.52
ZELTIQ Aesthetics 2017 10.1%–11.8% perpetuity growth 2.0%–3.0% $43.00–$62.30
Vascular Solutions 2016 9.4%–11.4% perpetuity growth 2.0%–3.0% $38.50–$55.25
EndoChoice Holdings 2016 11.8%–13.8% perpetuity growth 2.0%–4.0% $4.50–$7.10
St. Jude Medical 2016 7.0%–8.5% perpetuity growth 1.0%–2.0% $74.00–$114.00

Peer companies Guggenheim Securities selects most often

Chemed Corporation (4) · Amedisys, Inc. (3) · LHC Group, Inc. (3) · Almost Family, Inc. (3) · AtriCure, Inc. (2) · Nevro Corp. (2) · Addus HomeCare Corporation (2) · K2M Group Holdings Inc. (2) · Spectranetics Corp. (2)

Precedent transactions Guggenheim Securities cites most often

Given Imaging Ltd. / Covidien plc (4) · HeartWare International, Inc. / Medtronic plc (3) · Sage Products, LLC / Stryker Corporation (3) · Conceptus Inc. / Bayer Healthcare LLC (3) · Healthpoint Biotherapeutics / Smith & Nephew plc (3) · SonoSite, Inc. / Fujifilm Holdings Corporation (3) · Gentiva Health Services, Inc. / Kindred Healthcare, Inc. (2) · Harden Healthcare Holdings, Inc. / Gentiva Health Services, Inc. (2) · Vascular Solutions Inc. / Teleflex Inc. (2) · LDR Holding Corp. / Zimmer Biomet Holdings, Inc. (2) · Thoratec Corporation / St. Jude Medical, Inc. (2) · ZOLL Medical Corporation / Asahi Kasei Corporation (2) · AGA Medical Holdings, Inc. / St. Jude Medical, Inc. (2) · Micrus Endovascular Corp. / Johnson & Johnson (2) · ev3 Inc. / Covidien plc (2)

3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
See the Valuation database →